top of page

Enchondroma

Overview
• Enchondroma is a benign hyaline cartilage tumor, accounting for 20-25% of benign bone tumors.
• It arises from residual cartilage cells that fail to undergo necrosis after physeal growth.
• Can be solitary or multiple (Ollier’s disease, Maffucci syndrome).

Clinical Presentation

  • Often      asymptomatic, detected incidentally (except in hand lesions).

  • Hand      enchondromas: Pain due to bone expansion, cortical thinning, or      microfractures.

  • Long      bone enchondromas with pain: Rule out first intra-articular pathologies, atypical      cartilage tumor or chondrosarcoma

Associated Syndromes

  • Ollier’s      disease: Multiple enchondromas, unilateral, 20-50% malignant      transformation risk. Lesions are generally unilateral. Short stature, limb      length discrepancy, and angular deformities in bones and joints are      commonly seen.

  • Maffucci      syndrome: Enchondromas + soft tissue hemangiomas; higher malignancy      risk than Ollier’s. Due to      phleboliths, hemangiomas are also detected on X-rays.

Common Sites

  • Hands      (40-65%): Proximal phalanges > metacarpals > middle phalanges.

  • Long      bones: Femur, humerus, tibia (metaphyseal).

  • Rare      in carpal/tarsal bones or distal phalanges.

Imaging Features

  • X-ray:

    • Hands: Lytic,       sclerotic rim, bone expansion, cortical thinning, calcification is not       usually seen.

    • Long       bones: Metaphyseal, indistinct margins, endosteal scalloping,       matrix calcification.

  • CT: Evaluates      calcification and cortical integrity.

  • MRI: Assesses      soft tissue extension, peritumoral edema, contrast enhancement (for      differential diagnosis) and fat entrapment.

  • PET-CT: Useful      for enchondromatosis/pelvic lesions

Biopsy

  • Not      routine; reserved for atypical features (e.g., pain, growth, or imaging      suspicious for chondrosarcoma).

  • Target      less calcified, fat entrapment and heterogeneous areas on MRI. Biopsy      tract should align with potential surgical incision.

Treatment

  • Asymptomatic,      small (<4 cm), stable lesions: Annual monitoring.(BACTIP Protocole* : Birmingham Atypical Cartilage Tumor Imaging Protocol)

  • Surgical      indications:

    • Pain,       growth on follow-up, or pathologic fracture risk.

    • Techniques: Intralesional       curettage + adjuvant + bone-filler (PMMA/graft) ± fixation (fracture risk       in lower extremities).

    • Hand       lesions: Curettage alone/ Curettage and bone filler (PMMA/Graft)

Differential Diagnosis

  • Atypical      Cartilage Tumor (ACT):

    • WHO       2020 reclassified grade I chondrosarcomas in extremities as ACT (no metastasis risk but can recur).

    • Suspect       if pain, size >4 cm, generalized endosteal scalloping.

  • Chondrosarcoma:

    • Cortical       destruction, soft tissue involvement, axial skeleton location.

Mirels' score
metastatic fracture
vertebroplasty - cementation
humerus im nailing

Type

Tumor Length

Endosteal Scalloping

Management

1a

<4 cm

None

Discharge

1b

<4 cm

Focal

Follow-up in 3 years; refer to oncology or discharge based on changes

1c

<4 cm

Generalized

Immediate oncology referral

2a

≥4 cm

None

Follow-up in 3 years; refer to oncology or discharge based on changes

2b

≥4 cm

Focal

Follow-up at 1 & 3 years; refer to oncology or discharge

2c

≥4 cm

Generalized

Immediate oncology referral

3

any size

Aggressive features

Immediate oncology referral

The Birmingham Atypical Cartilage Tumor Imaging Protocol (BACTIB) classification

bottom of page